
Results
4
Stocks which the market has priced substantially different to their cash flows, which could imply risk.
4 companies
Grifols
Market Cap: €6.1b
Engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
GRF
€10.15
7D
0.4%
1Y
-19.2%
Almirall
Market Cap: €2.3b
Operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa.
ALM
€10.60
7D
-3.5%
1Y
-5.5%
Pharma Mar
Market Cap: €1.5b
A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally.
PHM
€83.95
7D
7.1%
1Y
1.5%
Labiana Health
Market Cap: €53.1m
Develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally.
LAB
€6.40
7D
-2.3%
1Y
63.3%